Ocugen partners with Roots Pharmaceutical for MENA gene therapy supply
What happened
Ocugen partnered with Roots Pharmaceutical to supply OCU400 in the Middle East and North Africa. Ocugen will manufacture the commercial supply of the gene therapy. The agreement includes an upfront license fee, potential initial development payments up to $4 million, and potential sales milestones up to $255 million, plus 22% royalties on net sales.
From manilatimes.net
Why it matters
The partnership establishes strategic commercial reach for Ocugen across the Middle East and North Africa. Roots Pharmaceutical aims to address the substantial unmet need for retinitis pigmentosa treatment in the region, where the disease prevalence is estimated to be 10 to 20 times higher than in the U.S. and EU.
From manilatimes.net
Who's involved
- OcugenWill manufacture and supply the gene therapy OCU400
- Middle EastIs the region where Roots Pharmaceutical will distribute the therapy
Keep exploring
The entities involved
-
Ocugen
biopharmaceutical company
Nothing else this week.
-
Middle East
geopolitical region encompassing Egypt and most of Western Asia, including Iran